HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (30) Citing Articles via Google Scholar Google Scholar Articles by Thrailkill, K. M. Articles by Fowlkes, J. L. Search for Related Content PubMed PubMed Citation Articles by Thrailkill, K. M. Articles by Fowlkes, J. L.

INVITED REVIEWS

Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues

Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children’s Hospital Research Institute, Little Rock, Arkansas

Diabetic osteoporosis is increasingly recognized as a significant comorbidity of type 1 diabetes mellitus. In contrast, type 2 diabetes mellitus is more commonly associated with modest increases in bone mineral density for age. Despite this dichotomy, clinical, in vivo, and in vitro data uniformly support the concept that new bone formation as well as bone microarchitectural integrity are altered in the diabetic state, leading to an increased risk for fragility fracture and inadequate bone regeneration following injury. In this review, we examine the contribution that insulin, as a potential anabolic agent in bone, may make to the pathophysiology of diabetic bone disease. Specifically, we have assimilated human and animal data examining the effects of endogenous insulin production, exogenous insulin administration, insulin sensitivity, and insulin signaling on bone. In so doing, we present evidence that insulin, acting as an anabolic agent in bone, can preserve and increase bone density and bone strength, presumably through direct and/or indirect effects on bone formation.

type 1 diabetes mellitus; type 2 diabetes mellitus; osteoblasts; osteoporosis; insulin receptors; hyperinsulinism

This article has been cited by other articles:

				S. Reinwald, R. G. Peterson, M. R. Allen, and D. B. Burr Skeletal changes associated with the onset of type 2 diabetes in the ZDF and ZDSD rodent models Am J Physiol Endocrinol Metab, April 1, 2009; 296(4): E765 - E774. [Abstract] [Full Text] [PDF]

				K. N. Ealey, J. Kaludjerovic, M. C. Archer, and W. E. Ward Adiponectin Is a Negative Regulator of Bone Mineral and Bone Strength in Growing Mice Experimental Biology and Medicine, December 1, 2008; 233(12): 1546 - 1553. [Abstract] [Full Text] [PDF]

				L. D. Mastrandrea, J. Wactawski-Wende, R. P. Donahue, K. M. Hovey, A. Clark, and T. Quattrin Young Women With Type 1 Diabetes Have Lower Bone Mineral Density That Persists Over Time Diabetes Care, September 1, 2008; 31(9): 1729 - 1735. [Abstract] [Full Text] [PDF]

				M. Monami, B. Cresci, A. Colombini, L. Pala, D. Balzi, F. Gori, V. Chiasserini, N. Marchionni, C. M. Rotella, and E. Mannucci Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients: A case-control study Diabetes Care, February 1, 2008; 31(2): 199 - 203. [Abstract] [Full Text] [PDF]

				Q. Zhong, T. Itokawa, S. Sridhar, K.-H. Ding, D. Xie, B. Kang, W. B. Bollag, R. J. Bollag, M. Hamrick, K. Insogna, et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E543 - E548. [Abstract] [Full Text] [PDF]

				T. Miazgowski, S. Pynka, M. Noworyta-Zietara, B. Krzyzanowska-Swiniarska, and R. Pikul Bone mineral density and hip structural analysis in type 1 diabetic men Eur. J. Endocrinol., January 1, 2007; 156(1): 123 - 127. [Abstract] [Full Text] [PDF]